$INT (-22,66 %) is probably haunted by short sellers. Short interest jumped from 0.5% to over 7% according to Marketscreener.... Reasons are probably suboptimal capital management from what I could find out. However, the financial information published before earnings is actually quite solid.

Could be a good follow-on opportunity.

Not a breathtaking performance in September, but every plus is taken. As my portfolio still largely consists of $RKLB (+6,56 %) and they haven't moved much, the portfolio has remained rather stable overall. But after the rapid rise in the summer, I would say a little break is more than deserved.

New positions in September: $3993 (+2,78 %) and $INT (-22,66 %)

October has already got off to a strong start and looks promising overall.

$INT (-22,66 %) I'm in now too. But already down 5%. I'm curious to see what will happen, it's now 1/3 of my portfolio. 🙂‍↕️✌️

Admit it, you're all waiting for new ideas!

Ok, here's one I've just invested in. I find $INT (-22,66 %) pretty exciting. Good story, sensible product, mega growth and still largely undiscovered and cheap.

Here's an interview I found with the CEO, which convinced me that this is an important technology and therefore an opportunity.

Mr. Lindahl, could you give me a brief overview of the vision and mission of Intellego Technologies and what makes the company's technology unique?

Claes Lindahl: With pleasure. Intellego's long-term goal is to become a global market leader in the UV industry, which has a wide range of applications. This includes healthcare and disinfection, but also industrial applications such as UV curing. One example: We have a global collaboration with Henkel in the adhesives industry. Our mission is to bring products of the highest quality to the market. We are convinced that this commitment to quality and technological

excellence is a key reason why we have been able to grow so quickly and enter into large-scale partnerships with companies such as Henkel and Likang in China.

What is special about your collaboration with Henkel and what are the goals of this partnership?

The collaboration combines Intellego's technology with Henkel's global distribution network. Together we are scaling a quality assurance tool for the UV curing market.

Could you give further examples of how your technology is used and in which industries?

One of our biggest areas of application today is UV disinfection in the healthcare sector. Our color indicators are used to check whether a disinfection process - for example in a hospital room - has been carried out properly. This is currently our most important sales driver.

Are there other companies serving this market with similar technologies? Steris, for example, is a large sterilization company. How do you differentiate yourselves?

Steris is indeed a giant, but their core business is sterilization, not UV disinfection. Sterilization is typically done with heat and steam and requires a higher level of cleanliness, while UV disinfection kills bacteria and viruses with UV radiation. Some companies such as Steris, 3M or Sweden's Getinge do produce colour indicators - but for sterilization, not UV disinfection. So far, none have entered the UV market, which is still relatively small and far less regulated than sterilization.

What are your financial targets for this year and the coming years?

We are aiming for continued strong growth. We have raised our targets for 2025 to over 70 million euros in sales and more than 40 million euros in EBIT. If we perform exceptionally well, we could raise these targets even further.

What milestones can investors expect in the coming months?

Investors should pay attention to three key figures: Sales, EBIT margin and cash flow. Growth is important, but stable margins and the generation of positive cash flow are just as crucial. These will be the most meaningful indicators of our progress. Can you explain more about the technology itself - what makes it unique?

In healthcare, UV disinfection typically consists of placing a large UV lamp or robot in a hospital room. The UV radiation kills bacteria and viruses on surfaces. However, the human eye cannot see UV light, so it is impossible to know whether all areas have been sufficiently irradiated. This is exactly where our color indicators come into play. They are distributed around the room and change color when they are exposed to sufficient UV radiation - clear proof that disinfection has taken place. What makes us special is the specificity of our indicators: they are calibrated so that they only react to the wavelengths that kill bacteria and viruses. Competing products often react to normal room light and generate false positive signals.

Our technology avoids this, and its reliability has been proven in 10-20 independent publications, many of them

hospital studies.

How easy is it to roll out your technology globally given the high demand for clean environments?

It would be extremely difficult for us as a company with 64 employees to roll it out on our own. That's why partnerships with companies like Henkel and Likang are so valuable. These collaborations allow our technology to reach global markets much faster - what would take us ten years, partners can do in six months.

Your margin expansion compared to the previous year has recently been remarkable. Why is that?

Our business model is almost like a software company. As soon as sales exceed a certain threshold, our very high gross margins - often 80 to 90 percent - have a strong impact. This has become increasingly apparent with the sales growth of recent years. We have also adjusted our pricing as we realized that some products were priced too low. These factors together explain the widening of margins. Of course, we are aware that this will not last forever - continuous innovation and new products are crucial to maintaining our position and defending margins against competition.

Highly profitable on the road in millions of Swedish kronor

EBIT is set to quadruple this year alone to around SEK 500 million and rise to SEK 1150 million in 2027 from SEK 870 million in 2026.

An exciting opportunity even for somewhat more conservative investors. Probably not a fast tenbagger, but in my view a potential doubler over the next 12 months.

Has anyone else looked into it?